文献速递心力衰竭与心肌病

维利西呱在射血分数保留的心力衰竭患者中的研究:SOCRATES-PRESERVED 结果

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
PubMed 文献 · Eur Heart J · 2017-01-01

SOCRATES-PRESERVED 是一项前瞻性、随机、安慰剂对照、双盲、2b 期剂量探索研究,纳入 477 例 HFpEF(射血分数≥45%)患者,评估维利西呱的耐受性和最佳剂量方案。主要终点为 12 周时 logNT-proBNP 和左心房容积(LAV)的变化,结果显示维利西呱与安慰剂无显著差异,但耐受性良好,10 mg 组生活质量(KCCQ-CSS)改善。

要点

  • 维利西呱在 HFpEF 患者中耐受性良好,10 mg 组不良事件 69.8%,安慰剂组 73.1%。
  • 12 周时 logNT-proBNP 和 LAV 变化与安慰剂无显著差异(P 值分别为 0.2017 和 0.3688)。
  • 10 mg 组 KCCQ-CSS 较基线平均改善 19.3 分,与安慰剂平均差异 9.2 分。

核心结论

  • 维利西呱耐受性良好,12 周时未改变 NT-proBNP 和 LAV,但与 HFpEF 患者生活质量改善相关。

研究设计与样本

  • 前瞻性、随机、安慰剂对照、双盲、2b 期剂量探索研究,纳入 477 例 HFpEF(射血分数≥45%)患者。

主要发现

  • pooled 三个最高剂量组 logNT-proBNP 变化:维利西呱 +0.038 ± 0.782 log(pg/mL)(n=195) vs 安慰剂 -0.098 ± 0.778 log(pg/mL)(n=73),双侧 P=0.2017。
  • pooled 三个最高剂量组 LAV 变化:维利西呱 -1.7 ± 12.8 mL(n=194) vs 安慰剂 -3.4 ± 12.7 mL(n=67),双侧 P=0.3688。
  • 维利西呱 10 mg 组不良事件 69.8%,安慰剂组 73.1%;10 mg 组血压与安慰剂相比无变化。
  • 维利西呱 10 mg 组 KCCQ-CSS 较基线平均改善 19.3 ± 16.3 分,与安慰剂平均差异 9.2 分。

关键数值与推荐

  • 维利西呱给药方案:每日一次 1.25 或 2.5 mg 固定剂量,或从 2.5 mg 起始滴定至 5 或 10 mg,或安慰剂,治疗 12 周。
  • 主要终点:12 周时 log 转换的 NT-proBNP 和左心房容积(LAV)较基线的变化。
  • 入组条件:HFpEF 射血分数≥45%,随机化在 HF 住院(75%)或门诊静脉利尿剂治疗(25%)后 4 周内。

临床怎么用

  • 维利西呱在 HFpEF 患者中耐受性良好,不良事件发生率与安慰剂相当,10 mg 组未观察到血压变化。
  • 维利西呱 10 mg 组观察到 KCCQ-CSS 改善,但与安慰剂平均差异 9.2 分需进一步研究验证。
  • 鉴于生活质量方面的鼓励性结果,维利西呱在 HFpEF 中的效应值得进一步研究,可能采用更高剂量、更长随访和额外终点。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To determine tolerability and the optimal dose regimen of the soluble guanylate cyclase stimulator vericiguat in patients with chronic heart failure and preserved ejection fraction (HFpEF). METHODS AND RESULTS: SOCRATES-PRESERVED was a prospective, randomized, placebo-controlled double-blind, Phase 2b dose-finding study in patients with HFpEF (ejection fraction ≥ 45%). Patients received vericiguat once daily at 1.25 or 2.5 mg fixed doses, or 5 or 10 mg titrated from a 2.5 mg starting dose, or placebo for 12 weeks. The two primary endpoints were change from baseline in log-transformed N-terminal pro-B-type natriuretic peptide (NT-ProBNP) and left atrial volume (LAV) at 12 weeks. Patients (N = 477; 48% women; mean age 73 ± 10 years; baseline atrial fibrillation 40%) were randomized within 4 weeks of HF hospitalization (75%) or outpatient treatment with intravenous diuretics for HF (25%) to vericiguat (n = 384) or placebo (n = 93). In the pooled three highest dose arms change in logNT-proBNP (vericiguat: +0.038 ± 0.782 log(pg/mL), n = 195; placebo: -0.098 ± 0.778 log(pg/mL), n = 73; one-sided P = 0.8991, two-sided P = 0.2017), and change in LAV [vericiguat: -1.7 ± 12.8 mL (n = 194); placebo: -3.4 ± 12.7 mL (n = 67), one-sided P = 0.8156, two-sided P = 0.3688] were not different from placebo. Vericiguat was well tolerated (adverse events: vericiguat 10 mg arm, 69.8%; placebo, 73.1%), with low discontinuation rates in all groups, and no changes in blood pressure at 10 mg compared with placebo. The pre-specified exploratory endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score improved in the vericiguat 10 mg arm by mean 19.3 ± 16.3 points [median 19.8 (interquartile range 10.4-30.7)] from baseline (mean difference from placebo 9.2 points). CONCLUSION: Vericiguat was well tolerated, did not change NT-proBNP and LAV at 12 weeks compared with placebo but was associated with improvements in quality of life in patients with HFpEF. Given the encouraging results on quality of life, the effects of vericiguat in patients with HFpEF warrant further study, possibly with higher doses, longer follow-up and additional endpoints.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017. PMID: 28369340. doi:10.1093/eurheartj/ehw593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。